Prentiss Smith & Co’s ResMed RMD Stock Holding History

Prentiss Smith & Co’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-115	Closed	-$13K	–	192
2018 Q3	$13K	Sell	115 -10	-8%	-$1.09K	0.01%	191
2018 Q2	$13K	Hold	125	–	–	0.01%	194
2018 Q1	$12K	Hold	125	–	–	0.01%	209
2017 Q4	$11K	Hold	125	–	–	0.01%	218
2017 Q3	$10K	Hold	125	–	–	0.01%	201
2017 Q2	$10K	Hold	125	–	–	0.01%	202
2017 Q1	$9K	Hold	125	–	–	0.01%	200
2016 Q4	$8K	Hold	125	–	–	﹤0.01%	211
2016 Q3	$8K	Hold	125	–	–	﹤0.01%	208
2016 Q2	$8K	Hold	125	–	–	﹤0.01%	222
2016 Q1	$7K	Hold	125	–	–	﹤0.01%	251
2015 Q4	$7K	Hold	125	–	–	﹤0.01%	262
2015 Q3	$6K	Hold	125	–	–	﹤0.01%	254
2015 Q2	$7K	Hold	125	–	–	﹤0.01%	228
2015 Q1	$9K	Hold	125	–	–	﹤0.01%	238
2014 Q4	$7K	Buy	+125	New	+$6.53K	﹤0.01%	259

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Prentiss Smith & Co's RMD Position: Q4 2018 in Review

Prentiss Smith & Co sold out of ResMed (RMD) in Q4 2018, closing a stake of 115 shares — an estimated $13K sold.

Prentiss Smith & Co first reported a position in RMD in Q4 2014 and held it in 16 quarters. The position peaked at $13K in Q3 2018. 502 funds tracked by Wall St. Rank hold RMD as of Q4 2018.

Prentiss Smith & Co reported no remaining ResMed position as of Q4 2018 after selling out during the quarter.
Prentiss Smith & Co sold 115 ResMed shares in Q4 2018, an estimated $13K.
Prentiss Smith & Co first reported a position in ResMed in Q4 2014 and held it in 16 quarters.
Prentiss Smith & Co's ResMed position peaked at $13K in Q3 2018.
502 funds tracked by Wall St. Rank held ResMed as of Q4 2018.

Based on Prentiss Smith & Co's 13F filing for Q4 2018, filed 15 Jan 2019.